These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17489112)

  • 1. CCR5 inhibitors: up and coming new agents.
    O'Neal R
    BETA; 2007; 19(2):15-9. PubMed ID: 17489112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV agents. Vicriviroc.
    TreatmentUpdate; 2008 Mar; 20(2):9-10. PubMed ID: 18661648
    [No Abstract]   [Full Text] [Related]  

  • 3. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.
    Lenz JC; Rockstroh JK
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1139-50. PubMed ID: 20712521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
    McKinnell JA; Saag MS
    Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better results from vicriviroc with new Trofile test.
    Proj Inf Perspect; 2008 Dec; (47):12. PubMed ID: 19227563
    [No Abstract]   [Full Text] [Related]  

  • 9. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety study of vicriviroc presented.
    Proj Inf Perspect; 2008 Dec; (47):13. PubMed ID: 19227564
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?
    Idemyor V
    HIV Clin Trials; 2005; 6(5):272-7. PubMed ID: 16306033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of virus entry: an antiviral mechanism of emerging prominence.
    Koszalka GW; Meanwell NA
    Curr Opin Investig Drugs; 2006 Feb; 7(2):106-8. PubMed ID: 16499279
    [No Abstract]   [Full Text] [Related]  

  • 15. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
    Fätkenheuer G
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():46-8. PubMed ID: 16385874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New CCR5 antagonist enters phase II trials. Drug would be first-line therapy.
    AIDS Alert; 2008 Aug; 23(8):89-90. PubMed ID: 18724488
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV-2 susceptibility to entry inhibitors.
    Borrego P; Taveira N
    AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
    Horster S; Goebel FD
    Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.